Health
AstraZeneca Says Key Lung Cancer Drug Improved Survival
- Company describes data as a breakthrough for patients
- Imfinzi is already approved for several other indications
This article is for subscribers only.
AstraZeneca Plc’s lung cancer drug improved survival in patients with a highly aggressive form of the disease, becoming the first immunotherapy to help these patients live longer, the company said.
Imfinzi showed statistically significant and clinically meaningful improvement in both slowing the progression of the disease and overall survival, according to initial results from an advanced study.